Kallikrein-Related Peptidases in Prostate Cancer: From Molecular Function to Clinical Application.
Prostate cancer is a leading contributor to male cancer-related deaths worldwide. Kallikrein-related peptidases (KLKs) are serine proteases that exhibit deregulated expression in prostate cancer, with KLK3, or prostate specific antigen (PSA), being the widely-employed clinical biomarker for prostate cancer. Other KLKs, such as KLK2, show promise as prostate cancer biomarkers and, additionally, their altered expression has been utilised for the design of KLK-targeted therapies. There is also a large body of in vitro and in vivo evidence supporting their role in cancer-related processes. Here, we review the literature on studies to date investigating the potential of other KLKs, in addition to PSA, as biomarkers and in therapeutic options, as well as their current known functional roles in cancer progression. Increased knowledge of these KLK-mediated functions, including degradation of the extracellular matrix, local invasion, cancer cell proliferation, interactions with fibroblasts, angiogenesis, migration, bone metastasis and tumour growth in vivo, may help define new roles as prognostic biomarkers and novel therapeutic targets for this cancer.
Cancer Program, Institute of Health and Biomedical Innovation, Queensland University of Technology , Brisbane, Australia.
Ruth A
RA
Fuhrman-Luck
Cancer Program, Institute of Health and Biomedical Innovation, Queensland University of Technology , Brisbane, Australia.
Daniela
D
Loessner
Cancer Program, Institute of Health and Biomedical Innovation, Queensland University of Technology , Brisbane, Australia.
Judith A
JA
Clements
biomarker; kallikrein-related peptidase; prostate cancer; protease
BJU Int. 2012 Dec;110(11):1654-60
23043563
Urology. 2011 Apr;77(4):1009.e1-8
21296394
Clin Chem. 2007 Aug;53(8):1423-32
17573418
Biochem Biophys Res Commun. 2001 Dec 21;289(5):1082-7
11741302
Nat Med. 2000 Nov;6(11):1248-52
11062536
Mol Cell Proteomics. 2012 Dec;11(12):1870-84
22986220
J Proteome Res. 2012 Apr 6;11(4):2386-96
22339264
Biol Chem. 2008 Jun;389(6):765-71
18627292
J Androl. 1999 Mar-Apr;20(2):220-9
10232657
Endocr Relat Cancer. 2005 Sep;12(3):631-43
16172196
Biochem Biophys Res Commun. 1993 Apr 30;192(2):940-7
7683467
J Biol Chem. 2006 May 5;281(18):12743-50
16517595
J Biol Chem. 2007 Nov 2;282(44):31852-64
17823117
Prostate. 2003 Sep 1;56(4):287-92
12858357
Int J Cancer. 1991 Nov 11;49(5):645-9
1718912
J Med Genet. 2004 Jul;41(7):545-9
15235027
Cell. 2011 Mar 4;144(5):646-74
21376230
Urology. 2003 May;61(5):1042-6
12736044
Int J Cancer. 2010 Feb 1;126(3):599-610
19795418
Exp Cell Res. 2010 Nov 15;316(19):3207-26
20727350
Prostate. 2005 Jan 1;62(1):1-13
15389820
BJU Int. 2013 Aug;112(3):313-21
23826841
Prostate. 2012 Oct 1;72(14):1588-94
22430591
J Urol. 2003 Nov;170(5):1787-91
14532777
J Urol. 1996 Feb;155(2):738-42
8558716
Biomaterials. 2010 Nov;31(31):7928-36
20688384
FEBS J. 2008 Mar;275(5):1003-17
18221492
Prostate. 2002 Feb 1;50(2):112-8
11816019
J Natl Cancer Inst. 1999 Oct 6;91(19):1663-9
10511594
Prostate. 2001 Jun 15;48(1):1-6
11391681
Curr Pharm Des. 2007;13(7):719-27
17346186
BJU Int. 2015 Jun;115(6):913-20
24589357
Prostate. 2008 Aug 1;68(11):1143-51
18500692
Biol Chem. 2006 Jun;387(6):749-59
16800736
Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1246-51
9990009
Clin Cancer Res. 1995 Oct;1(10):1089-94
9815898
Prostate. 2008 Jun 15;68(9):945-54
18386289
Prostate Cancer Prostatic Dis. 2011 Dec;14(4):286-94
21826098
J Natl Cancer Inst. 2009 Mar 18;101(6):374-83
19276453
J Biol Chem. 1997 Aug 22;272(34):21582-8
9261179
J Am Soc Mass Spectrom. 2007 Jul;18(7):1249-64
17553692
Clin Chem. 2005 Aug;51(8):1432-42
15961548
J Clin Oncol. 2010 Mar 1;28(7):1099-105
20100959
Prostate. 2013 Aug;73(11):1191-201
23620432
Prostate. 2002 May 1;51(2):126-32
11948967
Biochem Biophys Res Commun. 2004 Oct 22;323(3):1084-90
15381110
Biol Chem. 2010 Jan;391(1):85-95
19919178
Prostate. 2011 Dec;71(16):1780-9
21520157
Pharmacol Ther. 2013 Feb;137(2):200-15
23064233
J Cell Physiol. 2005 Feb;202(2):361-70
15389580
Prostate. 1999 Jun 1;39(4):246-61
10344214
N Engl J Med. 2012 Mar 15;366(11):981-90
22417251
Prostate. 2011 Nov;71(15):1680-90
21446007
J Clin Oncol. 2002 Apr 1;20(7):1874-9
11919247
Mol Cancer Res. 2008 Jun;6(6):1043-51
18567807
Prostate. 2007 Mar 1;67(4):348-60
17221837
Proc Natl Acad Sci U S A. 2013 Jul 9;110(28):E2572-81
23798432
Eur Urol. 2012 Nov;62(5):745-52
22704366
Eur Urol. 2013 Nov;64(5):693-9
23683475
J Clin Oncol. 2010 May 20;28(15):2493-8
20421547
Epigenetics. 2012 Sep;7(9):1037-45
22874102
J Biol Chem. 2007 Jan 26;282(4):2405-22
17110383
Eur J Oral Sci. 2011 Dec;119 Suppl 1:206-16
22243248
Clin Cancer Res. 2008 Mar 1;14(5):1355-62
18316555
Br J Cancer. 1999 Dec;81(8):1269-73
10604721
Neoplasia. 2005 Mar;7(3):241-52
15799824
J Clin Invest. 1987 Aug;80(2):281-5
3611349
Glycobiology. 2010 Jan;20(4):452-60
20008118
Prostate. 2011 Nov;71(15):1595-607
21394741
Int J Oncol. 2007 Jun;30(6):1493-8
17487371
J Biol Chem. 2005 Apr 15;280(15):14628-35
15713679
Endocr Rev. 2010 Aug;31(4):407-46
20103546
Biol Chem. 2006 Jun;387(6):817-24
16800746
Biochemistry. 2001 Dec 18;40(50):15341-8
11735417